Agenus presents clinical data demonstrating durable responses of botensilimab/balstilimab combination in metastatic microsatellite stable colorectal cancer at asco gi

Lexington, mass., jan. 23, 2023 (globe newswire) -- agenus (nasdaq: agen), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced clinical data from the mss crc (microsatellite stable colorectal cancer) 70 patient cohort of a phase 1b study of botensilimab (multifunctional fc-enhanced anti-ctla-4) in combination with balstilimab (anti-pd-1) in patients with chemotherapy and/or immunotherapy-resistant tumors. the larger dataset continues to demonstrate that this combination offers superior efficacy and durability compared to what has been reported for standard of care and other investigational therapies in third line metastatic mss crc. the data were presented in the opening late-breaking oral session at the american society of clinical oncology – gastrointestinal cancers symposium (asco gi) in san francisco, ca on saturday jan 21 2023.
AGEN Ratings Summary
AGEN Quant Ranking